Idiotypic Suppression of B-Cell-Derived Tumors
The expression of idiotypic determinants on immunoglobulin-producing monoclonal neoplasms has been recognized for over a decade. Tumor idiotypes have two major applications: they are surface determinants against which highly specific immunity can be induced and used for therapy, and they are targets for immunoregulatory cells and antibodies, so that the tumors can serve as models for the regulation of nonneoplastic lymphocytes. Since the first demonstration of idiotype-specific tumor immunity against murine myelomas,1 the general validity of this approach has been convincingly established by numerous investigators. It is now clear that anti-idiotypic antibodies and/or T lymphocytes can suppress the growth or mediate the rejection of murine and human B-cell lymphomas and leukemias,(2,3) a variety of antibody-secreting myelomas,(4,5) and “hybridomas” produced by fusion of immune B lymphocytes and drug-marked myelomas.(6) The clinical applicability of such approaches is limited by the problem of producing specific anti-idiotypic antibodies and effector T lymphocytes against individual neoplasms. However, modern advances in techniques for long-term cell culture and somatic cell hybridization may well make it feasible to direct immunotherapeutic regimens against the idiotypic determinants present on B-cell-derived neoplasms.
KeywordsMyeloma Cell Accessory Cell Myeloma Protein Immunoregulatory Cell Delay Hypersensitivity
Unable to display preview. Download preview PDF.
- 8.Sato, G. H., and Ross, R. (eds.), 1979, Hormones and Cell Culture, Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.Google Scholar
- 17.Sy, M.-S., Nisonoff, A., Germain, R. N., Benacerraf, B., and Greene, M. I., 1981, Antigen- and receptordriven regulatory mechanisms. VIII. Suppression of idiotype-negative p-azobenzenearsonate-specific T cells results from the intereaction of an anti-idiotypic second-order T suppressor cell with a cross-reactive idiotype-positive p-azobenzenearsonate primed T cell target, J. Exp. Med. 153:1415–1425.PubMedCrossRefGoogle Scholar